RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Novel Therapeutics May Lower LDL in Familial Hypercholesterolemia
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 2
SP 30
OP 31
DO 10.1177/155989771302020
UL http://mdc.sagepub.com/content/13/2/30.abstract
AB Familial combined hyperlipidemia is a highly atherogenic disorder that affects 1% to 2% of the Western world [Shoulders CC et al. Hum Mol Genet 2004]. It occurs in approximately 20% of patients who develop coronary heart disease before age 60 [Aouizerat BE et al. Am J Hum Genet 1999]. This article discusses the need for continued research of treatments for familial hypercholesterolemia (FH). Emerging therapies include apolipoprotein B (ApoB) inhibitors, microsomal triglyceride transfer protein (MTP) inhibitors, and proprotein convertase subtilism kexin 9 (PCSK9) inhibitors [Alonso R et al. Expert Rev Cardiovasc Ther 2013].